Protecting staff and reducing cost of care can be as easy as implementing the AEROECLIPSE® II BAN® Nebulizer into your treatment pathway.
A study conducted in an active Emergency Department found that switching to the AEROECLIPSE® II BAN® Nebulizer resulted in fewer infections among the healthcare team and reduced the number of staff sick days, saving hospitals significant costs in sick and call-back pay. The Copelin study concluded that BAN® Nebulizer-based therapy not only improved patient outcomes, but also minimized transmission risks and positive influenza tests.
